Director/PDMR Shareholdings
04 December 2023
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and
diagnostic applications, has been notified of the following purchases of
ordinary shares of 4 pence each in the Company ("Ordinary
Shares") by certain Directors of Fusion.
Simon Douglas, Non-Executive Chair, has purchased 100,565 Ordinary Shares
at an average price of 4.96 pence per share. Following this purchase,
Simon Douglas directly holds 356,365 Ordinary Shares, representing
approximately 0.60 per cent. of the Company's issued share capital.
Adrian Kinkaid, Chief Executive Officer, has purchased 101,847 Ordinary Shares at an average price of 4.90 pence per share. Following this purchase, Adrian Kinkaid holds 245,847 Ordinary Shares, representing approximately 0.41 per cent. of the Company's issued share capital.
Further details of the respective purchases are outlined in the tables
below.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
|---|---|---|---|---|---|---|
| a) | Name | Simon Douglas | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Chair | ||||
| b) |
Initial notification /Amendment | Initial notification | ||||
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) |
Description of the financial instrument, type of
instrument Identification code |
ordinary shares of 4p each in Fusion Antibodies
plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of Ordinary Shares |
||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
- See above - See above |
||||
| e) | Date of the transaction | 4 December 2023 | ||||
| f) | Place of the transaction | XLON, London Stock Exchange | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
|---|---|---|---|---|---|---|
| a) | Name | Adrian Kinkaid | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) |
Initial notification /Amendment | Initial notification | ||||
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) |
Description of the financial instrument, type of
instrument Identification code |
ordinary shares of 4p each in Fusion Antibodies
plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of Ordinary Shares |
||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
- See above - See above |
||||
| e) | Date of the transaction | 4 December 2023 | ||||
| f) | Place of the transaction | XLON, London Stock Exchange | ||||
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Adrian Kinkaid, Chief Executive
Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
| James Reeve/Vivek Bhardwaj (Corporate
Finance) Tony Quirke (Sales and Corporate Broking) |
||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the discovery and
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
design, generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation using
Fusion's proprietary CDRx TM platform and the
production of antibody generating stable cell lines to provide material
for use in clinical trials. Since 2012, the Company has
successfully sequenced and expressed over 250 antibodies and
successfully completed over 200 humanisation projects and has an
international, blue-chip client base, which has included eight of the
top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and
diagnostic companies to develop innovative products in a timely and
cost-effective manner for the benefit of the global healthcare industry.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.